Series A · Healthtech
Altis Labs raises $25m Series A co-led by OrbiMed and Qiming US
Altis’ Series A supports broader cancer models and commercial deployment with biopharma partners.
Financing follows a Phase 3 trial-data analysis
Altis Labs announced a $25m Series A on September 17, 2026, co-led by OrbiMed and Qiming Venture Partners USA. Innovation Endeavors, Benchstrength, Fusion Fund and the Cancer Breakthrough Fund also participated.
The round followed Johnson & Johnson’s independent post-hoc analysis of the MARIPOSA Phase 3 trial. Altis reported that its imaging response measure detected a treatment effect ahead of later survival readouts. The proceeds support extending models to more cancer types and expanding commercial deployment with global biopharma partners.
Funding history
Series A · This round$25M